NASDAQ:ELDN Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis $2.95 -0.05 (-1.67%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.80▼$3.0550-Day Range$2.38▼$3.1952-Week Range$1.07▼$3.35Volume53,644 shsAverage Volume116,548 shsMarket Capitalization$73.19 millionP/E RatioN/ADividend YieldN/APrice Target$11.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Eledon Pharmaceuticals alerts: Email Address Eledon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside295.5% Upside$11.67 Price TargetShort InterestHealthy0.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.21) to ($0.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.65 out of 5 starsMedical Sector273rd out of 936 stocksPharmaceutical Preparations Industry122nd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingEledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Eledon Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.52% of the outstanding shares of Eledon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEledon Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eledon Pharmaceuticals has recently decreased by 24.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEledon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEledon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELDN. Previous Next 3.3 News and Social Media Coverage News SentimentEledon Pharmaceuticals has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eledon Pharmaceuticals this week, compared to 1 article on an average week.Search Interest9 people have searched for ELDN on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders11.70% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eledon Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Eledon Pharmaceuticals are expected to grow in the coming year, from ($1.21) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eledon Pharmaceuticals is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eledon Pharmaceuticals is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEledon Pharmaceuticals has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Eledon Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Read More ELDN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELDN Stock News HeadlinesJuly 22, 2024 | msn.com2 Penny Stocks Wall Street Expects to Soar Over 400%July 2, 2024 | globenewswire.comEledon to Participate in the Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.June 17, 2024 | investorplace.comPenny Stock Picks: 3 Companies Poised to Graduate to the Big LeaguesJune 11, 2024 | investorplace.com3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024June 3, 2024 | globenewswire.comEledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationMay 10, 2024 | markets.businessinsider.comEledon Pharmaceuticals’ Tegoprubart Shows Promising Trial Results and Fuels Buy RatingMay 9, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 9, 2024 | globenewswire.comEledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comEledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)May 7, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionMay 7, 2024 | markets.businessinsider.comEledon Pharmaceuticals’ Tegoprubart Shows Promising Clinical Advancements, Reinforcing Buy Rating and Elevated Price TargetMay 7, 2024 | msn.comNano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased ConfidenceMay 7, 2024 | finance.yahoo.comEledon Pharmaceuticals Announces Oversubscribed $50 Million Private PlacementMay 7, 2024 | globenewswire.comEledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionApril 29, 2024 | msn.com2 Penny Stocks That Wall Street Predicts Will Soar Over 300%See More Headlines Receive ELDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELDN CUSIPN/A CIK1404281 Webnovustherapeutics.com Phone(949) 238-8090FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$11.67 High Stock Price Target$16.00 Low Stock Price Target$9.00 Potential Upside/Downside+295.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-45.60% Return on Assets-42.76% Debt Debt-to-Equity RatioN/A Current Ratio11.30 Quick Ratio11.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.45 per share Price / Book0.86Miscellaneous Outstanding Shares24,813,000Free Float21,910,000Market Cap$73.20 million OptionableOptionable Beta0.91 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. David-Alexandre C. Gros M.D. (Age 52)Ph.D., CEO & Non Independent Director Comp: $807.96kDr. Steven N. Perrin Ph.D. (Age 58)President, Chief Scientific Officer & Non Independent Director Comp: $603.9kMr. Paul Sean Little (Age 59)CFO & Principal Accounting Officer Comp: $611.71kMr. John HerbergerVice President of Technical OperationsMr. Bryan E. Smith J.D. (Age 44)General Counsel, Corporate Secretary & Chief Compliance Officer Comp: $377.14kDr. David Hovland Ph.D.Chief Regulatory OfficerDr. Eliezer Katz F.A.C.S.FACS, M.D., Chief Medical OfficerMore ExecutivesKey CompetitorsNeos TherapeuticsNASDAQ:NEOSAlimera SciencesNASDAQ:ALIMFoghorn TherapeuticsNASDAQ:FHTXProcaps GroupNASDAQ:PROCDesign TherapeuticsNASDAQ:DSGNView All CompetitorsInstitutional OwnershipCM Management LLCBought 20,000 shares on 5/14/2024Ownership: 0.645%Vanguard Group Inc.Bought 273,703 shares on 5/10/2024Ownership: 3.906%View All Institutional Transactions ELDN Stock Analysis - Frequently Asked Questions How have ELDN shares performed this year? Eledon Pharmaceuticals' stock was trading at $1.80 at the beginning of the year. Since then, ELDN shares have increased by 63.9% and is now trading at $2.95. View the best growth stocks for 2024 here. How were Eledon Pharmaceuticals' earnings last quarter? Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) issued its earnings results on Thursday, May, 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. How do I buy shares of Eledon Pharmaceuticals? Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELDN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELDN Stock Alerts